How much does it cost to build a formoterol (Foradil) manufacturing plant?
The specific cost to build a manufacturing plant for formoterol branded as Foradil is not provided in the available information you supplied, and public price figures for the exact “Foradil manufacturing plant” are not typically published as a single, comparable number because cost depends heavily on the facility design and regulatory scope.
What drives the manufacturing plant cost for inhaled formoterol products?
Even for the same active ingredient (formoterol), total facility cost usually varies based on choices like:
- whether the plant produces only the active pharmaceutical ingredient (API) or also produces finished inhalation products
- batch sizes, capacity (e.g., kilograms of API vs. number of inhalers/canisters)
- whether formulation and filling are done on-site or outsourced
- required cleanroom classification and containment level for handling powders and aerosols
- sterility/bioburden requirements for the dosage form (many inhaled products are not “sterile” in the injectable sense, but they still have strict quality and contamination controls)
- environmental controls, solvent recovery, waste handling, and emissions permits
- regulatory target (e.g., generic vs. brand-level standards), validation effort, and audit scope
Does “plant cost” mean CAPEX for APIs, inhalers, or both?
When people search for “manufacturing plant cost,” they often mean different CAPEX categories:
- API production facilities (chemical synthesis, purification, crystallization, drying, packaging of API)
- drug product facilities (formulation, device integration, filling, sealing, labeling)
- both, if the site is vertically integrated
If you clarify which scope you mean, the cost expectation can be narrowed, because integrated API + finished dose sites are much more expensive than a packaging/filling site that relies on externally sourced API.
What data is usually needed to estimate cost reliably?
A practical cost estimate usually requires at least:
- location (country/state) and labor/cost environment
- required output (annual API tonnage and/or number of inhaler units)
- dosage form and device type (DPI capsules vs. other inhalation devices)
- whether the site is new-build or a retrofit of existing capacity
- target standard and whether it’s for commercial production, clinical supply, or both
If you’re trying to budget a project, what’s the best next step?
If you share whether you mean (1) API synthesis, (2) finished inhaler manufacturing (including filling/device assembly), or (3) both—and the target annual capacity and country/region—I can help translate that into a budgeting framework and identify the most relevant cost drivers for that exact scope.
Sources
No sources were provided in the prompt, and no searchable reference material was included to cite specific Foradil plant CAPEX figures.